<DOC>
	<DOCNO>NCT01683175</DOCNO>
	<brief_summary>This study compare 2-year Disease Free Survival Rate ( DFSR ) post radical operation IIIA Non-Small Cell Lung Cancer ( NSCLC ) patient Epidermal Growth Factor Receptor ( EGFR ) 19 21 exon mutation treat Erlotinib v NP chemotherapy adjuvant therapy .</brief_summary>
	<brief_title>Erlotinib Post Radical Operation NSCLC Patients With EGFR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>IIIA NSCLC patient accord TMNstaging Lung Staging Standard version 7 2009 , confirm histopathology cytology radical operation , EGFR exon 19 deletion mutation exon 21 L858R single base substitution ; Accept study adjuvant therapy within 6 week post radical operation ; ECOP PS 01 ; Life expectancy ≥12 week ; Hematology : absolute neutrophil count ( ANC ) ≥1.5×10^9/L ; platelet count ≥100×10^9/L ; hemoglobin concentration ≥ 9.0 g/dL ( permit maintain hematologic criterion blood transfusion ) ; Liver Function : TBil ≤1.5xULN ; ALT AST ≤2.5xULN ; Renal Function : Cr ≤1.25xULN , Ccr ≥60ml/min ; Female patient childbearing potential must negative serum urine pregnancy test within 7 day study treatment ; Signed inform consent form patient his/her legal representative ; Comply study protocol procedure , able take oral medication ; Aged ≥18 year ≦75 year ; Eligible patient reproductive potential ( sex ) must agree use reliable method birth control enrollment , study period least 30 day last dose study therapy ; Having treat HerTarget therapy , i.e . erlotinib , gefitinib , cetuximab , trastuzumab ; Having treat systemic antitumor therapy NSCLC , include cytotoxic therapy , target medication treatment ( i.e . monoclonal antibody ) , investigational therapy ; Having local radiotherapy NSCLC ; Upper gastrointestinal physiological disorder , malabsorption syndrome , intolerance oral medication , active peptic ulcer ; The finding radical operation lymph node extracapsular invasion , fusion , dissection lymph node positive pathology ; Diagnosed malignant tumor besides NSCLC within 5 year prior study treatment ( except simple surgical resection 5year disease free survival , cure situ cervical carcinoma , cure basal cell carcinoma bladder epithelial tumor ) ; Confirmed recurrent cancer Clinical objective evidence ( pathology radiography image ) study adjuvant therapy ; Known hypersensitivity platinum , Vinorelbine , EGFRTKI agent relevant component formulation ; Uncontrolled eye inflammation infection , potential circumstance lead eye inflammation infection ; Active interstitial lung disease ( ILD ) clinical evidence ; patient comorbidities , motalic disorder , abnormal finding physical examination laboratory test suspect contraindication study therapy high risk study treatment complication ; Any unstable systemic disease , include active infection , uncontrolled hypertension , unstable angina , angina start late 3 month , Congestive heart failure ( NYHA ≥ II ) , myocardial infarction within 6 month prior enrollment , medication treatment severe arrhythmia , liver , renal metabolic disease ; know HIV infection Pregnant breastfeeding woman ; ECOG PS ≥2 ; Mixed small cell lung cancer ; Other condition investigator evaluate patient eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Erlotinib</keyword>
	<keyword>adjuvant therapy</keyword>
	<keyword>radical operation</keyword>
	<keyword>IIIA NSCLC</keyword>
	<keyword>EGFR mutation</keyword>
</DOC>